Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.
In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.

Welcome to the PN learning hub focused on key scientific education on bullous pemphigoid, featuring ADVENT resources.
Professor Matthias Augustin highlights the high prevalence of both atopic and non-atopic comorbidities in patients with PN, including increased risks of cardiovascular events and all-cause mortality.
Explore the clinical features, complex burden, and underlying mechanisms of PN.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.
Professors Matthias Augustin and Sarina Elmariah evaluate how targeted therapies transform the management of prurigo nodularis, addressing the itch-scratch cycle and broader manifestations such as lesions.

Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Professor Sarina Elmariah describes how IL-4 and IL-13, key drivers of type 2 inflammation, uniquely contribute to manifestations of prurigo nodularis beyond itch.

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.